Ovarian Cancer Clinical Trial
Relief Band as an Adjunct to Antiemetic Therapy in Patients Who Receive Mod to Highly Emetogenic Chemotherapy
Summary
The primary study hypotheses are that, without increasing doses of breakthrough medications or device intolerance, the Nometexâ„¢ device worn for 5-days beginning with the day of chemotherapy administration in women with ovarian or advanced endometrial or cervical cancer will, as an adjunct to standard-of-care anti-emetics, reduce vomiting episodes, and reduce the severity of nausea.
The secondary hypotheses are that the Nometexâ„¢ device reduces acute (Day 1) emetic episodes, day 1 and days 2-5 severity of nausea, and delayed (days 2-5) emetic episodes without increasing doses of breakthrough medications or device intolerance.
Eligibility Criteria
Inclusion Criteria:
Women with ovarian (including fallopian tube) or advanced endometrial or cervical cancer
Chemotherapy-naïve or who have had previous chemotherapy exposure, but who have not yet received the first infusion
18 years of age or older, and can provide cognizant informed consent presenting to the Helen F. Graham Cancer Center
ECOG Status of 0-2
Standardized Antiemetic Regimen
Exclusion Criteria:
Pre-existing or at-risk for a peripheral neuropathy in region of device placement
Implanted cardiac pace maker
Nickel or other metal allergies
Previous experience with median nerve/P6 stimulation
Receiving concurrent radiation therapy
Previous participants of this study will be excluded from future participation in this study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Newark Delaware, 19713, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.